AbbVie Reports Positive Phase 3 Results for RINVOQ® in Vitiligo
NORTH CHICAGO, Ill., October 29, 2025 — AbbVie Inc. (NYSE: ABBV) announced positive topline results from two replicate Phase...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
NORTH CHICAGO, Ill., October 29, 2025 — AbbVie Inc. (NYSE: ABBV) announced positive topline results from two replicate Phase...
INDIANAPOLIS, Ind., October 24, 2025 — In a landmark decision for veterinary medicine and regulatory preparedness, Elanco Animal Health...
Hyderabad, India — September 18, 2025 — Sai Life Sciences has inaugurated Unit VI, a dedicated facility for the...
MANHATTAN, Kan., August 2025 — Kansas State University, Iowa State University, and University College Dublin have announced a landmark...
Dateline – Silver Spring, MD, September 18, 2025 – The U.S. Food and Drug Administration (FDA), in coordination with...
